NOTE: STOCKS IN THIS WATCHLIST ARE NOT GEARED TOWARDS ANY SPECIFIC TYPE OF TRADING (DAY, SWING, LONG). HOWEVER, THEY ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE CHART. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
Stocks highlighted in this watchlist include: $SNES, $DEST, $CASI, $ATOS
SNES: Float of 7.95 million with 1.18% short. SenesTech, Inc., a leader in technology for managing animal pest populations through fertility control, will exhibit ContraPest®, the EPA-approved fertility control product for controlling rat infestations, at PestWorld 2017 in Baltimore, MD on October 24-27. It also announced a national distribution agreement with Univar for ContraPest®. In addition to distribution, Univar will be marketing and selling ContraPest throughout its network.
DEST: Float of 11.7 million shares with 11.93% short. Destination Maternity Corporation, the world's leading maternity apparel retailer, today announced that, based on preliminary voting tabulations, Destination stockholders have supported the re-election of all four Destination nominees to the Company's Board of Directors. As of April 29, 2017Destination Maternity operates 1,157 retail locations in the United States, Canada, and Puerto Rico, including 511 stores, predominantly under the trade names Motherhood Maternity®, A Pea in the Pod® and Destination Maternity®, and 646 leased department locations
CASI: Float of 36.55 million shares with 0.31% short. CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced that it has entered into definitive agreements with certain institutional and accredited investors, including existing shareholders, to purchase approximately $23.8 million of securities in a registered direct offering. The offering was expected to close on or about October 17, 2017, subject to satisfaction of customary closing conditions.
ATOS: Float of 11.37 million shares with 10.38% short. Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today it will host a conference call on October 25, 2017 at 10 am EDT to discuss preliminary results from its Phase 1 dose escalation study of its proprietary oral Endoxifen. Endoxifen is an active metabolite of the FDA-approved drug tamoxifen, which is currently used to treat breast cancer and for breast cancer prevention in high risk patients.
Preliminary results were announced on September 14th. All objectives were successfully met:1. Safety: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen.
2.Tolerability: Topical Endoxifen was well tolerated at each dose level and for the dosing duration utilized in the study.
.Pharmacokinetics: Topical Endoxifen crossed the skin barrier when applied daily to the breast, as demonstrated by low but measurable Endoxifen blood levels detected in a dose-dependent fashion.
These data demonstrate the suitability of topical endoxifen for further clinical development.